A new method for measuring of molecular mobility in glassy materials has been developed using terahertz spectroscopy. The absorption level of amorphous drugs at terahertz frequencies below Tg correlates with the stability of the drug as an amorphous solid. The molecular mobility responsible for the glass crystallisation significantly decreases at around a universal value of 0.67 Tg. This explains why the commonly used rules of thumb for glasses to remain stable below 0.8 Tg or Tg – 20 K do not work reliably.
These results reveal a unique and completely novel opportunity to predict and test the stability of amorphous drugs by measuring the molecular mobility below the glass transition temperature of drugs and formulations at terahertz frequencies. It is not possible to measure this information using conventional dielectric spectroscopy due to the practical difficulties of measuring at low temperatures.
We are interested in meeting industrial contacts who would be willing to collaborate on developing this method further.
Visit http://thz.ceb.cam.ac.uk for more information of our group.
This policy explains what information we gather when you visit our web site, and explains how that information is used.
Cookies are small files which sit on your computer and record specific interactions between you and this website, and in some cases, other websites. This information is sometimes shared with the University of Cambridge, and in other cases, third parties. Below is more detail about the cookies we use, what they record and who the information is shared with. You are of course free to disable cookies.
Functionality lost by disabling cookies or not giving consent
If you disable cookies, or don't opt in to receive them from these sections of our site, some functionality will not be available.
How to disable cookies
Your web browser will have an option you select which will block cookies. Below are links to popular web browsers, and how to block cookies using them.
Cookies set by third party websites
|Name||Used by||Description||More information|
In common with most web sites, this site automatically logs certain information about every request made of it (see below for more details). This information is used for system administration, for bug tracking, and for producing usage statistics.
We may collect and process the following data about you:
- Information that you provide by filling in forms provided on this website for a specific purpose. By supplying this information you are consenting to the PSSRC holding and using it for the purposes for which it was provided.
- If you contact us, we may keep a record of that correspondence.
The following data is automatically collected for each request:
- The name or network address of the computer making the request. Note that under some (but not all) circumstances it may be possible to infer from this the identity of the person making the request. Note also that the data recorded may be that of a web proxy rather than that of the originating client
- The username, when known during authenticated (logged in) access to the site
- The date and time of connection
- The HTTP request, which contains the identification of the document requested
- The status code of the request (success or failure etc.)
- The number of data bytes sent in response
- The contents of the HTTP Referrer header supplied by the browser
- The content of the HTTP User-Agent header supplied by the browser
Logging of additional data may be enabled temporarily from time to time for specific purposes.
In addition, the computers on which the web site is hosted keep records of attempts (authorised and unauthorised) to use them for purposes other than access to the web server. This data typically includes:
- the date and time of the attempt,
- the service to which access was attempted,
- the name or network address of the computer making the connection,
- and may include details of what was done or was attempted to be done.
Disclosure and uses of personal information
We use information held about you in the following ways:
- to ensure that content from our website is presented in the most effective manner for you and for your computer or device by gathering aggregate information about our users using it to analyse the effectiveness and popularity of this website
- to allow you to participate in interactive features of our service, when you choose to do so
We may disclose your personal information to third parties in the following circumstances:
- if we have obtained your consent to do so
- when we are required or authorised by law, court order, regulatory or governmental authority to disclose your personal data
Relevant subsets of this data may be passed to computer security teams as part of investigations of computer misuse involving this site.
In addition, this site uses Google Analytics to help us analyse site usage and to improve it. To support this, selected information about your interaction with the site is sent to Google for them to analyse on our behalf. For more information about Google Analytics see http://www.google.com/analytics/.
Links to other websites
Laboratory of Pharmaceutical Technology
Tel.: + 32 (0) 9 264 80 54
Fax: + 32 (0) 9 222 82 36
Main Research Interests
The main research interest of Professor Remon is in the field of solid dosage forms, especially pellets, sustained release matrix formulations, coprocessing, bioadhesion and pediatric formulations.
Jean Paul Remon obtained his degree as a Pharmacist in 1973, a degree in Industrial Pharmacy in 1974 and his Ph.D. degree in 1981 at Ghent University. After research fellowships at University of Keele (UK) (Biochemistry Research Unit) in 1983 and at the College of Pharmacy and Science (Philadelphia, US) in 1984, he became professor at Ghent University in 1985.
He is member of several pharmaceutical societies (APV, AAPS, APGI, Controlled Release Society) and became a AAPS Fellow in 2005.
Since 1996 he is Dean of the Faculty of Pharmaceutical Sciences (Ghent University).
He is co-author of more than 200 research papers.
M.Sc., Helsinki, 1991
Ph.D., Helsinki, 1995
Docent, Helsinki, 1997
Adjunct professor, Helsinki, 2003
Professor in Industrial Pharmacy, Helsinki, 2006
University of Helsinki
Faculty of Pharmacy, Formulation and Industrial Pharmacy
P.O. Box 56 (Viikinkaari 5 E)
00014 University of Helsinki
Main Research Interests
Prof. Anne M. Juppo holds the professorship in Industrial Pharmacy in University of Helsinki since 2006. Industrial pharmacy is a discipline which includes manufacturing, development, marketing and distribution of drug products including quality assurance of these activities. Her research at the University of Helsinki is focused at the moment on the novel technologies (excipients and processes) for pharmaceutical solid formulation on biopharmaceuticals and solid formulations for veterinary, peadiatric and elderly patients.
Her previous appointments are in pharmaceutical industry: AstraZeneca R&D Mölndal (1996-2006), where she worked as research scientist, project leader, team manager and as Principal Scientist in Product Development. Her areas of interest in these positions were controlled release preparations, particle technology, pellet technology and polymer coatings. In addition to the industrial position she had an adjunct professorship (2003-2005) in University of Helsinki. Prior to her position at AstraZeneca, she worked with solid state and particle characterisation in Orion Pharma, Finland (1992-1995).
Staatsexamen Pharmazie, Münster, 1991
Diplompharmazeut, Greifswald, 1992
Dr. rer. nat. (Pharmaceutical Technology), Münster, 1996
Habilitation (Pharmaceutical Technology), Münster, 2004
Professor for Pharmaceutical Technology, Düsseldorf, 2004
Institute of Pharmaceutics and Biopharmaceutics
Main Research Interests
Prof. Jörg Breitkreutz holds the professorship in Pharmaceutical Technology in University of Düsseldorf since 2004. His research is focused on paediatric formulations, pharmaceutical excipients, drug delivery devices, process analytical technologies and taste prediction. He is involved in numerous development projects for paediatric drugs and holds several patents for paediatric medicines.
Jörg Breitkreutz studied Pharmacy from 1987 to 1991 at the Westphalian Wilhelms-University of Münster, Germany. He finished his PhD in 1996 at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under supervision of Prof. Rüdiger Gröning. From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, as the Head of Product Coordination. In 1997 he went back to the university in Münster to work on his habilitation thesis (2004) on pediatric drug formulations. In 2004 he became professor for pharmaceutical technology at the Institute of Pharmaceutics and Biopharmaceutics at the Heinrich-Heine-University in Düsseldorf, Germany. Since 2009 he is the head of the Pharmacy department in Düsseldorf. He currently is member of the European Paediatric Formulation Initiative (EuPFI) and board member of the International Association for Pharmaceutical Technology (APV).